Healthcare

According to the U.S., marijuana was the most widely used drug globally in 2014 with around 183 million users. Such a large user base makes it highly lucrative taxable opportunity, which is influencing various governments worldwide to initiate studies regarding legalization of the drug for medicinal use. The National Institute on Drug Abuse is conducting research on cannabis (marijuana) to treat numerous diseases and conditions such as autoimmune disease, pain, inflammation, seizures, mental disorders, and substance abuse disorders.

Request for Sample Copy of Research Report@

https://www.coherentmarketinsights.com/insight/request-sample/40

Market Dynamics

According to the Medical Marijuana, Inc., an estimated size of the legal marijuana industry in the U.S. was US$ 7.1 billion in 2016 with increase of 25% Y-o-Y. In 2016, 28 states in the U.S. have legalized marijuana for medicinal purpose with some more gearing up for votes on the recreational use of marijuana. California, Nevada, Maine, and Massachusetts states in November 2016, voted to legalize the recreational use of marijuana. The accelerated pace of legalization of cannabis (marijuana) in the U.S. has attracted the attention of global investors in the medical cannabis market.

Market Taxonomy

This report segments the global medicinal cannabis on the basis of point of sale, active ingredient and therapeutic application. On the basis of point of sale, the global medical cannabis market is classified into dispensaries, online pharmacy, and hospital pharmacy. Active ingredients of medicinal cannabis include tetrahydrocannabinol (THC) and Cannabidiol (CBD). Therapeutic Application categorized into pain, arthritis, neurological disease, and other applications.

Key features of the study:

• This report provides in-depth analysis of medicinal cannabis in medical sector and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2016 as the base year

• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players

• It profiles leading players in the global medicinal cannabis for medical sector market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans

• Key companies covered as a part of this study include BOL Pharma, Tilray, Medreleaf Corporation, Aurora Cannabis, Inc., Canopy Growth Corporation, Insys Therapeutics, Inc., Aphria, Inc., MGC Pharmaceuticals Limited, GW Pharmaceuticals, plc and Medical Marijuana Inc.

Detailed Segmentation:

• Global Medical Cannabis Market, By Point of Sale:

  • Dispensaries

  • Online Pharmacy

  • Hospital Pharmacy

• Global Medical Cannabis Market, By Active Ingredient:

  • Tetrahydrocannabinol (THC)

  • Cannabidiol (CBD)

• Global Medical Cannabis Market, By Therapeutic Application:

  • Pain

  • Arthritis

  • Neurological Disease

    • Epilepsy

    • Multiple Sclerosis

    • Other Neurological Applications

  • Other Applications

• Global Medical Cannabis Market, By Geography:

  • North America

    • By Country:

      • U.S.

Request for Discount Before Buying This Business Reports@

https://www.coherentmarketinsights.com/insight/request-discount/40

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1–206–701–6702

Email: sales@coherentmarketinsights.com

Diabetes is one of most prevalent chronic diseases worldwide. According to WHO (World Health Organization), diabetes was one of top three leading causes of mortality in 2012. The diabetes vaccine currently under development has significant potential in younger age group (Below 20 years age), who are characterized by a stronger autoimmune response to combat infection from specific viruses. Diabetes vaccine is being developed to strengthen the body’s response against enterovirus called coxsackievirus B1, wherein it senses enterovirus and produces immune response to destroy it.

Request for Sample Copy of Research Report@

https://www.coherentmarketinsights.com/insight/request-sample/1367

High global prevalence of type 1 diabetes is expected to aid in growth of the market over the forecast period

High global prevalence and incidence of type 1 diabetes is, inadvertently expected to create a conducive environment for growth of the diabetes vaccine market. According to the International Diabetes Federation’s (IDF) Diabetes Atlas 2017, around 425 million patients are suffering from diabetes worldwide by end of 2017. Of this, one million people (children and adolescents below 20 years of age) are suffering from type 1 diabetes, with around 150,000 new cases reported each year.

Furthermore, patients suffering from type 1 diabetes need constant monitoring and may also require insulin externally, which has to be taken intramuscularly every day. This becomes difficult for children. Cost associated with insulin therapy is also relatively high.

Diabetes Vaccine Market Taxonomy

On the basis of age group, the global diabetes vaccine market is segmented into:

• Up to 20 years of age
• Above 20 years of age

On the basis of end user, the global diabetes vaccine market is segmented into:

• Hospitals
• Clinics
• Others

North America market is expected to exhibit high growth, followed by Europe and Asia Pacific markets over the forecast period

North America is expected to exhibit high growth in the global diabetes vaccine market over the forecast period. This is owing to increasing incidence of diabetes and high resultant healthcare burden in the U.S. For instance, according to IDF, 17,100 new cases were detected in 2017 in the U.S. Around US$ 377 billion was spent over entire diabetes disease range, which accounts for about 52% of the total healthcare expenditure on diabetes worldwide. Significant part of which goes into maintaining constant blood sugar in type 1 by use of insulin. According to statistics released by American Diabetes Association, in 2017, around 193,000 people under 20 years of age in the U.S. were estimated to be diagnosed with diabetes, which accounts for 0.24% of this population. This inadvertently, is expected to create a conducive environment for growth of the market. U.S. has maximum number of children and adolescent(under age 20) with Type 1 diabetes at range of 1,69,600 in 2017,this is followed by India with highest cases type 1 diabetes after the U.S at range of 1,28,500 as reported by IDF.

Developments in the diabetes vaccine market

• Imcys— a Belgium-based biotech company— announced plans to commence its clinical trial in 2018 for new diabetes vaccine to treat type 1 diabetes. It uses modified peptides called imotopes, which spurs specific type of immune cell to kill immune cells that work on the insulin producing beta cells.
• Moreover, in 2017, Massachusetts General Hospital Immunobiology Laboratory presented findings of clinical trial at 75th Scientific Sessions of the American Diabetes Association, related to use of BCG vaccine to treat autoimmune response in type 1 diabetes. BCG vaccine could induce a permanent gene expression that restores regulatory T cells, thereby preventing the immune system attack, which is observed in type 1 diabetes. It is currently under phase two clinical trial.

Request for Discount Before Buying This Business Reports@

https://www.coherentmarketinsights.com/insight/request-discount/1367

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1–206–701–6702

Email: sales@coherentmarketinsights.com

Fibrosarcoma is a rare type of soft tissue malignant tumour composed solely of fibre-forming connective tissue called as fibroblasts. Although, this condition can occur at any age, it is commonly diagnosed between the age of 30-60 years. Patients suffering from genetic conditions such as retinoblastoma, nevoid basal cell carcinoma syndrome are more prone to develop fibrosarcoma. However, precise cause of disease is unknown. Furthermore, individuals undergoing radiation therapy or having lymphedema or get exposed to chemicals such as thorium dioxide vinyl chloride or arsenic are more prone to fibrosarcoma. This disease is symptomized by muscular pain, which increases exponentially with time.

Request for Sample Copy of Research Report@

https://www.coherentmarketinsights.com/insight/request-sample/1495

Fibrosarcoma Drugs Market Taxonomy:

By Type:

• Adult Fibrosarcoma
• Infantile Fibrosarcoma

By Active Ingredient:

• Doxorubicin Hydrocholride
• Ifosfamide
• Dacarbazine
• Pazopanib Hydrochloride
• Other Active Ingredient

By Route of Administration:

• Oral
• Injectable

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies

Fibrosarcoma Drugs Market Driver

Increasing research activities are expected to fuel the growth of fibrosarcoma drugs market over the forecast period. Fibrosarcoma being malignant tumor requires early removal through complete eradication of malignant cells by chemotherapy. Currently available chemotherapy includes side-effects such as acquirance of multi-drug resistance (MDR), severe side-effects and high rate of reoccurrence, which in turn demands for safer drug for chemotherapy. For instance, Loxo Oncology Inc., 2017, received US FDA approval for investigational new drug application for LOXO 195, a next-generation TRK inhibitor for treatment of patients with cancers that have acquired resistance to initial TRK therapy such as larotrectinib. Moreover, in the same year, LOXO oncology announced partnership with Bayer for the global development and commercialization of Larotrectinib and LOXO-195. The novel drug combination studies, clinical trial for targeted drug delivery and genetic profile based medication are expected to boost growth of the fibrosarcoma drugs market over the forecast period.

Increasing prevalence of fibrosarcoma is expected to augment growth of the fibrosarcoma drugs market. According to American Society of Clinical Oncology, 2017, around 3260 individuals were diagnosed by primary bone cancer in U.S. out of which 4% of adults are suffering from fibrosarcoma and prevalence of the disease is higher in men than in women. Currently, diagnosis facility lacks in early and accurate detection of fibrosarcoma. Therefore, rising awareness for disease and advancement in diagnostic as well as therapeutic procedures are expected to propel growth of the fibrosarcoma drugs market. Furthermore, companies, universities, and institutes are taking initiatives to provide inexpensive, readily available drugs with less side-effects as compared to present drugs that will help key players to strengthen product portfolio, in turn driving growth of the fibrosarcoma drug market.

Fibrosarcoma Drugs Market- Regional Analysis

The global fibrosarcoma market is projected to hold dominant position in North America over the forecast period, due to increasing research activities leading to better fibrosarcoma treatment. Furthermore, well-developed healthcare infrastructure is fuelling growth of fibrosarcoma market. Asia Pacific is expected to be fastest growing market over the forecast period due to developing healthcare infrastructure and rising awareness regarding conditions of fibrosarcoma.

Fibrosarcoma Drugs Market- Competitor

Major players operating in fibrosarcoma drugs market include Cadila Healthcare Limited, Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Baxter International Inc., Eli Lilly and Company, Pfizer limited, Johnson & Johnson., and Celon Laboratories Pvt. Ltd.

Request for Discount Before Buying This Business Reports@

https://www.coherentmarketinsights.com/insight/request-discount/1495

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1–206–701–6702

Email: sales@coherentmarketinsights.com

Desmoplastic Small Round Cell Tumor (DSRCT) refers to a rare kind of aggressive soft tissue cancer that usually begins at abdomen and hematogenously disseminates to the liver. According to the National Institute of Health, the disease primarily affects children and young adults, as is more prevalent in males than that in females. According to the Health Program of European Union, desmoplastic small round cell tumor is extremely rare and only a few hundred cases have been reported worldwide till 2011 since its first description in 1989. Moreover, according to National Cancer Intelligent Network, Public Health England, only three incidence cases of DSRC were reported between 2010 and 2013 in England.

Request for Sample Copy of Research Report@

https://www.coherentmarketinsights.com/insight/request-sample/1569

Desmoplastic Small Round Cell Tumor Treatment Market: Market Dynamics

Increasing incidence of genetic disorders and cancer is one of the major factors responsible for growth of the global desmoplastic small round cell tumor treatment market. According to a report published by Genetics Education Center, University of Kansas Medical Center 2012, 12% of the hospital admissions in the U.S. accounted for treatment of genetic causes in 2013. Moreover, according to the American Cancer Society 2017, the cancer occurring in stomach, small intestine, and gastrointestinal cavity are one of the most common of the rare cancer of the digestive systems. According to the Cancer Research UK 2016, rare cancers affects around 2 in 100,000 people. Additionally, increasing research and development to improve conditions of the patients suffering with rare cancers is also responsible to augment the market growth.

Desmoplastic Small Round Cell Tumor Treatment Market: Regional Insights

On the basis of region, the global desmoplastic small round cell tumor treatment market by Coherent Market Insights is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds a dominant position in the global desmoplastic small round cell tumor treatment market, owing to government and non-government initiatives undertaken to increase awareness regarding the rare cancers. For instance, the National Organization for Rare Disorders and Rare Cancer Alliance is focusing on offering information and provide support to adult and pediatric patients by providing them with cancer information, treatment options, and rare cancer differences. Additionally, extensive research and development to determine the underlying cause and early detection of these diseases is also being conducted in North America making the region a leader in the global market. For instance, the Mayo Foundation of Medical Education & Research is focusing on very specific research to determine the factors that are responsible to delay the diagnosis of soft tissue sarcomas in patients. On the other hand, Asia Pacific is expected to gain significant traction in the market, owing to improving healthcare infrastructure and research funding by government and non-government organizations. For instance, the Australian Government, Department of Health invested US$ 13 Million to stimulate clinical trial registry for under-researched health priorities, such as rare cancers and rare diseases.

Desmoplastic Small Round Cell Tumor Treatment Market: Competitive Analysis

Key players operating in the global desmoplastic small round cell tumor treatment market include Glentham Lifesciences Ltd., Novartis AG, NantCell, Inc., Daiichi Sankyo, Inc., F. Hoffmann-L-Roche, and others.

Desmoplastic Small Round Cell Tumor Treatment Market: Market Taxonomy:

On the basis of treatment type, the global desmoplastic small round cell tumor treatment market is segmented into:

Chemotherapy Drugs

Doxorubicin

Vincristine

Etoposide

Carboplatin

Cyclophaophamide

Surgical Tumor Removal

Radiotherapy

On the basis of end user, the global desmoplastic small round cell tumor treatment market is segmented into:

Hospitals

Cancer Treatment Centers

Others

Request for Discount Before Buying This Business Reports@

https://www.coherentmarketinsights.com/insight/request-discount/1569

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1–206–701–6702

Email: sales@coherentmarketinsights.com